RT Journal Article
T1 Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
A1 Oriol, Albert
A1 Vives, Susana
A1 Hernández Rivas, Jesús M.
A1 Tormo, Mar
A1 Heras, Inmaculada
A1 Rivas, Concepción
A1 Bethencourt, Concepción
A1 Moscardó, Federico
A1 Bueno, Javier
A1 Grande, Carlos
A1 del Potro, Eloy
A1 Guardia, Ramon
A1 Brunet, Salut
A1 Bergua, Juan
A1 Bernal, Teresa
A1 Moreno, M.José
A1 Calvo, Carlota
A1 Bastida, Pilar
A1 Feliu, Evarist
A1 Ribera, Josep M.
K1 acute lymphoblastic leukemia
K1 relapse
K1 rescue treatment
K1 prognostic factors
K1 Leucemia-Linfoma Linfoblástico de Células Precursoras
K1 Recurrencia
K1 Resultado del Tratamiento
K1 Pronóstico
AB BACKGROUNDAbout one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die. The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia.DESIGN AND METHODS. We analyzed the characteristics, the outcome and the prognostic factors for survival after first relapse in a series of 263 adult patients with acute lymphoblastic leukemia (excluding those with mature B-cell acute lymphoblastic leukemia) prospectively enrolled in four consecutive risk-adapted PETHEMA trials.RESULTS. The median overall survival after relapse was 4.5 months (95% CI, 4-5 months) with a 5-year overall survival of 10% (95% CI, 8%-12%); 45% of patients receiving intensive second-line treatment achieved a second complete remission and 22% (95% CI, 14%-30%) of them remained disease free at 5 years. Factors predicting a good outcome after rescue therapy were age less than 30 years (2-year overall survival of 21% versus 10% for those over 30 years old; P<0.022) and a first remission lasting more than 2 years (2-year overall survival of 36% versus 17% among those with a shorter first remission; P<0.001). Patients under 30 years old whose first complete remission lasted longer than 2 years had a 5-year overall survival of 38% (95% CI, 23%-53%) and a 5-year disease-free survival of 53% (95% CI, 34%-72%).CONCLUSIONSThe prognosis of adult patients with acute lymphoblastic leukemia who relapse is poor. Those aged less than 30 years with a first complete remission lasting longer than 2 years have reasonable possibilities of becoming long-term survivors while patients over this age or those who relapse early cannot be successfully rescued using the therapies currently available.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2010
FD 2010-04
LK http://hdl.handle.net/10668/466
UL http://hdl.handle.net/10668/466
LA en
NO Oriol A, Vives S, Hernandez-Rivas JM, Tormo M, Heras I, Rivas C, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica-the Hematology Journal. 2010;95(4):589-96
NO Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 10, 2025